Immunome IMNM Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's operating lease right-of-use assets in other assets?
- Immunome (IMNM) reported operating lease right-of-use assets in other assets of $2.83M in Q1 2026.
- How has Immunome's operating lease right-of-use assets in other assets changed year-over-year?
- Immunome's operating lease right-of-use assets in other assets decreased by 32.1% year-over-year, from $4.16M to $2.83M.
- What is the long-term trend for Immunome's operating lease right-of-use assets in other assets?
- Over 4 years (2021 to 2025), Immunome's operating lease right-of-use assets in other assets has grown at a 56.2% compound annual growth rate (CAGR), from $500K to $2.98M.